<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Volery, Maryse</dc:creator>
  <dc:creator>Scherz, Valentin</dc:creator>
  <dc:creator>Jakob, William</dc:creator>
  <dc:creator>Bandeira, Diane</dc:creator>
  <dc:creator>Deggim-Messmer, Vanessa</dc:creator>
  <dc:creator>Lauber-Biason, Anna</dc:creator>
  <dc:creator>Wildhaber, Johannes</dc:creator>
  <dc:creator>Falquet, Laurent</dc:creator>
  <dc:creator>Curtis, Nigel</dc:creator>
  <dc:creator>Zimmermann, Petra</dc:creator>
  <dc:date>2020-06-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Introduction: There is compositional overlap between the maternal intestinal  microbiome, the breast milk microbiome and the infant oral and intestinal microbiome.  Antibiotics cause profound changes in the microbiome. However, the effect of  intrapartum and early-life antibiotics on the maternal intestinal and breast milk  microbiome, and the infant oral and intestinal microbiome, and whether effects are  only short term or persist long term remain uncertain. Methods and analyses: In this prospective cohort study, we will use metagenomic  sequencing to determine: (1) the effect of intrapartum antibiotics on the composition of  the breast milk, and the infant oral and intestinal microbiome, including the  development and persistence of antibiotic resistance; (2) the effect of antibiotic  exposure in the first year of life on the composition of the infant oral and intestinal  microbiome, including the development and persistence of antibiotic resistance; (3)  the effect of disruption of the infant oral and intestinal microbiome on health outcomes  and (4) the compositional overlap between the maternal intestinal microbiome, the  breast milk microbiome and the infant oral and intestinal microbiome. Ethics and dissemination: The ABERRANT study has been approved by the  commission cantonale d’éthique de la recherche sur l’être humain (CER-VD) du  Canton de Vaud (#2019–01567). Outcomes will be disseminated through publication  and will be presented at scientific conferences. Trial registration number NCT04091282.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/unifr/documents/308785</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/308785/files/zim_spa.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1136/bmjopen-2019-036275</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>BMJ Open. - 2020, vol. 10, no. 6, p. e036275</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Study protocol for the ABERRANT study: antibiotic-induced disruption of the maternal and infant microbiome and adverse health outcomes — a prospective cohort study among children born at term</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
